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What is already known about the subject 
Warfarin is a drug with high inter-individual variability and although numerous studies have been 
undertaken to determine an individual’s response to the dose given in the maintenance phase, little 
has been done to predict an individual’s potential response to the initial loading regimen. 
What this paper adds  
The aim of the loading regimen is to bring the International Normalisation ratio into the required 
therapeutic range. This study proposes a method for pre-classifying an individual’s response to the 
proposed loading regimen. The method takes into account other variables that may influence the 
response and with a high degree of accuracy classes the potential response as being either below 
therapeutic range, within therapeutic range or above therapeutic range 
Abstract 
Background and purpose 
The dose regimen of Warfarin is separated into two phases. Firstly a loading dose is given, which is 
designed to bring the International Normalisation Ratio (INR) to within therapeutic range. Then a 
stable maintenance dose is given to maintain the INR within therapeutic range. In the United 
Kingdom (UK) the loading dose is usually given as three individual daily doses, the standard loading 
dose being 10mg on days one and two and 5mgs on day three, which can be varied at the discretion 
of the clinician. However, due to the large inter-individual variation in the response to Warfarin 
therapy, it is difficult to identify which patients will reach the narrow therapeutic window for target 
INR, and which will be above or below the therapeutic window. The aim of this research was to 
develop a methodology using a neural networks classification algorithm and data mining techniques 
to predict for a given loading dose and patient characteristics if the patient is more likely to achieve 
target INR or more likely to be above or below therapeutic range.   
Experimental Approach 
Multilayer perceptron (MLP) and 10-fold stratified cross validation algorithms were used to 
determine an artificial neural network to classify patients' response to their initial Warfarin loading 
dose.  
Key Results 
The resulting neural network model correctly classifies an individual’s response to their Warfarin 
loading dose over 80% of the time. As well as taking into account the initial loading dose, the final 
model also includes demographic, genetic and a number of other potential confounding factors.  
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Conclusion and implications 
With this model clinicians can predetermine whether a given loading regimen, along with specific 
patient characteristics will achieve a therapeutic response for a particular patient. Thus tailoring the 
loading dose regimen to meet the individual needs of the patient and reducing the risk of adverse 
drug reactions associated with Warfarin.  
Keywords 
Warfarin, Narrow therapeutic window, loading dose, neural networks 
Introduction  
Warfarin is an anticoagulant drug, which is the front line treatment for individuals at risk of 
thrombosis. Although Warfarin is effective in many cases, its effectiveness is subject to high inter-
patient variability, with some patients requiring small doses, as low as 1mg per day and others 
relatively high doses, up to 20mg per day. Another drawback to the use of Warfarin is the high risk of 
adverse events, including haemorrhage. A study by Pirmohamed et al, 2004 showed that Warfarin is 
responsible for approximately 10% of all hospital admissions for adverse drug reactions. Hence the 
requirement to provide patients with an individualised dose that maximises the efficacy of the drug 
whilst at the same time minimising the risk of potential adverse reactions.  
The International Normalisation Ratio (INR), a measure of the clotting tendency of blood is used to 
monitor a patient’s response to the drug. The usual therapeutic range for INR is between 2 and 3; 
however, individuals with prosthetic heart values can have higher values between 3 and 4. The 
dosing regimen of Warfarin is divided into two phases. Initially, a 3 day loading phase is given to 
bring a patient’s INR, measured on day 7, into the therapeutic range and then a maintenance dose is 
given to maintain the patients INR within therapeutic range. A number of algorithms have been 
proposed to estimate a patient’s maintenance dose (e.g. Gage et al, 2008, Schelleman, 2008, Zhu, 
2007, Sconce, 2005). The International Warfarin Pharmacogenetics Consortium used an ordinary 
least-squares linear regression modelling method to develop a pharmacogenetic algorithm that 
predicts the square root of the dose and incorporates both genetic and clinical data (The 
International Warfarin Pharmacogenetics Consortium, 2009). They found that greatest benefits from 
inclusion of the genetic profiles into their model were observed for the two extreme groups of 
patients: those in the 46.2% of the population that required 21 mg or less of warfarin per week and 
those that required 49 mg or more per week for therapeutic anticoagulation. In (McDonald et al, 
2008), using data on maintenance dose response for 17396 patients, the authors performed a 
comparison study of three types of model: polynomial, auto-regression/moving average with 
exogenous variable (ARMAX) (Hannan, 1976), and neural network (NN)  in predicting INR values. 
Using historical data on patients' INR measuments, though no genetic data, McDonald et al showed 
that continuously-updating neural network models predicted future INR measurements best of the 
three types of models.  However, there have been few studies investigating the response of patient’s 
to specific loading dose regimens. In the UK loading doses are normally three daily doses of 
Warfarin, the most common being 10mgs on days one and two and 5mgs on day three. However, 
this can be varied at the discretion of the clinician. In particular, lower doses, e.g. 5mgs on each of 
the three days, can be prescribed if the patient is thought to be frail or has an increased risk of 
bleeding. Previously unpublished work (Lane and Biktasheva, 2008) showed that patients given a 
3 
 
conservative loading regimen were unlikely to achieve an INR within therapeutic range irrespective 
of their individual characteristics. As it is well known that a patient response depends on both 
patient's characteristics and the loading dosage, and some combinations of the two result in 
counterintuitive responses, it seems to be the main difficulty preventing the lineage of the Warfarin 
loading dosage decision based on pure patients characteristics. At present, there is no optimal 
approach for determining the most suitable loading regimen for a specific patient.              
A patient’s response to Warfarin can be confounded by a number of factors. Demographic factors 
such as age, race or gender (Takahashi et al, 2006, Kamali et al, 2004) can have a significant impact 
on how the body responds to the prescribed dose, other factors such as co-medications, e.g. 
Amiodarone, and diet; particularly vitamin K intake can also influence response (Wells et al, 1994, 
Ansell et al, 2008). More recently genetic variations have also been identified, particularly in the 
genotypes CYP2C9 and VKORC1, which have a major impact on how the body responds to Warfarin 
therapy (Zhu et al, 2007).  
Regression models make use of statistical analysis to assess significance of each covariate proposed 
for the model in terms of how they affect the outcome of interest so non-significant (unless deemed 
clinically important) covariates can be excluded from the model. Then, given a set of measurements 
the regression models provide a prognostic formula for predicting a specific outcome value or 
probability of a specific response when the outcome is binary or categorical. This makes regression 
models easy to understand and interpret by clinicians. However, linear regression has a significant 
drawback: it does not work well for nonlinear problems, so to improve performance it requires fine 
tuning of nonlinear kernels, adaptive regression splines, etc.  Published regression algorithms often 
explain less than 50% of the variability in the outcome variable, particularly when applied to datasets 
other than the one used to derive the algorithm (International Warfarin Pharmacogenetics 
Consortium, Klein et al, 2009). A neural network approach implicitly detects all complex nonlinear 
relationships between independent and dependent variables, and is remarkably resilient to the 
noise always present in large data sets. Also, as a pattern recognition tool, neural network can 
provide classification of the response when more than two classes are present. It has been 
demonstrated that neural networks can be applied successfully for Warfarin maintenance dose 
prediction (Solomon et al, 2004) and to predict the daily INR level of individual patients (Narayaman 
et al, 1993). The results were promising, but further investigation was needed. 
 
The objective of the study reported in this manuscript was to apply data-mining techniques and 
neural network models to obtain high accuracy classification of patients’ response to their Warfarin 
loading dose regimen, taking into account demographic, genetic and other measurable confounding 
factors. The aim was to identify which patients would achieve the therapeutic INR range during the 
initial loading stage, which would be below the required threshold and which would be above the 
therapeutic window, that is to predict the three possible types of individual response: “in 
therapeutic range”, “under load”, and “over load”. We were also interested in determining if 
additional INR measurements on day 4, 5, and 6, which currently are not in clinical practice but were 
available for this study, can improve predictability of an individual patient's response to Warfarin 
loading regimen. 
Information on 500 patients taking Warfarin was available for the study. Data was collected on the 
patients’ demographic and genetic variables, as well as on whether or not they were taking the 
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antiarrhythmic drug Amiodarone, their loading dose regimen, baseline INR, and INR measurements 
on days 4, 5, 6 and 7. The stratified cross validation data mining technique was used to ensure that 
the patterns of response to Warfarin loading dose regimen are of general application. 
Methods 
Data from patients who had started Warfarin treatment, irrespective of indication, between 
November 2004 and March 2006 were included in the analysis after having obtained written 
informed consent. A total of 500 patients were recruited from the Royal Liverpool and Broadgreen 
University Hospital NHS Trust and University Hospital Aintree, Liverpool, UK. All patients were 
informed of the nature of the study prior to being enrolled and the only exclusion criteria was the 
refusal to give written informed consent. The study was approved by Birmingham South Research 
Ethics Committee. The mean age of the cohort was 68.36 years, 275 (54.9%) were male and 45 
(9.0%) were also taking the drug Amiodarone. Two genes VKORC1 and CYP2C9 were genotyped. For 
the VKORC1 haplotype, 65 (13%) were GG, 189 (37.7%) were AA and 208 (41.5%) were 41.5% the 
remainder were unknown (7.8%). For the CYP2C9 genotype, 347 (69.3%) were the wild type *1/*1, 
96 (19.2%) were *1/*2, 42 (8.4%) were *1/*3, 4 (0.8%) were *2/*2, 8 (1.6%) were *2/*3 and 3 
(0.6%) were *3/*3. One-hundred and thirty-three (45%) were prescribed the standard loading 
regimen of 10mg, 10mg, 5mg over the 3 days, 19 (6.5%) had a loading dose regimen of 10mg, 10mg, 
10mg, similarly 19 (6.5%) had a loading dose regimen of 7mg,7mg,7mg, 15 (5.1%) had a loading dose 
of 5mg,5mg,5mg, and the remaining 36.9% had loading dose regimens ranging from 0mg, 7mg, 7mg 
to 10mg, 10mg, 12mg. 
 
The complete list of the covariates is as follows: age (yrs), gender (male=1, female=0), body-weight 
(kg), height (metres), BSA, BMI, Amiodarone (yes=1, no=0), VKORC1 (GG=0, AA=1, AG=2), CYP2C9 
(*1/*1=0, *1/*2=1, *1/*3=2, 2*/*2=3, 2*/*3=4, *3/*3=5), loading dose day1, loading dose day 2, 
loading dose day 3, INR day 4, INR day 5, INR day 6 and baseline INR. The total loading dose, equals 
sum of loading doses 1, 2 and 3 was later included in the model.    
Prior to applying the Perceptron algorithm to the dataset, some pre-processing was required to deal 
with missing data. The data pre-processing/cleaning steps are illustrated in Figure. 1.  
Firstly, individuals missing all body measurements (height, weight, BMI) and demographic data (sex, 
age) were excluded from the dataset. Then, individuals missing all loading dose information on days 
1-3 were excluded from the dataset. Due to clinics being closed on weekends etc., very few 
individuals had a full complement of the INR measurements on days 4, 5, 6, with a small minority 
having missing INR measurements on day 7. Consequently, missing INR values on day 7 were 
replaced by the value nearest to day 7 that is by the INR value on day 8. If missing both days 7 and 8, 
then INR values on day 7 were replaced by the INR value on day 6. The day 7 INR values were then 
categorised as follows; response below target (categorised 1), in-range (categorised 2), and above 
target (categorised 3). After that, the individuals with all missing interim measurements of INR day 4, 
5, and 6 were excluded. Finally the remaining missing values were replaced with 0. 
The final dataset used in classification experiments contained 294 individual observations, on 16 
explanatory variables and one outcome variable, the categorised response to the given loading dose. 
Later, the total loading was included the model as an extra explanatory variable.  
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Figure 1: Data pre-processing flow. 
 
A Matlab implementation of the Multilayer Perceptron, MLP (Haykin, 1999) was used to construct 
the classification algorithm. A very useful and concise explanation of the Perceptron algorithm can 
be found in the Appendix of Solomon et al, 2004. The artificial neural network uses a training data 
set to learn the mapping of input instances into known “class” outputs. After the mapping is 
established, it can be used to predict classification of new data. The data set, described above, was 
used to train the MLP to map the input instances of patients’ individual data into their known 
individual categorised INR day 7 taken as “class” output. After the iterative training, the most 
appropriate weights for the input data are obtained, and the algorithm is able to provide accurate 
classification predictions for new patients.  
Although the MLP algorithm is well developed and wildly used for classification problems, its success 
is highly dependent on the quality/representativeness of the training data and a good choice of the 
MLP architecture such as number of hidden layers/neurons and choice of activation functions, which 
are in turn problem dependent, so in practice it has to be defined empirically by trial and error.     
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The models were validated on independent data using stratified 10-fold cross validation (Witten and 
Frank, 2005). As the standard loading regimen of Warfarin is varied at the discretion of an 
experienced clinician, there is a bias in the data set towards the majority of the patients who reach 
the therapeutic INR on day 7, however, the main challenge is to identify those patients who have the 
risk of under- or over-load. The random selection of records into the training and validation/test sets 
does not take into account the unequal distribution of response categories, thus failing to improve 
classification beyond 60% (D. Fillingham, 2011). That is why stratification of the independent testing 
set is necessary to preserve the same representativeness proportion of each category as in the 
training set. Following the data mining 10-fold stratified cross-validation technique, the original 
dataset is divided into 10 subsets, with the proportion of categories in each subset being the same 
as the proportion of categories in the whole sample. Then 9 of these subsets are used for training 
with the 10th subset used for validation. Then, each of the 10 subsets is used in turn as the test set 
with the rest of the data being used for training. Finally, after 10 runs the average accuracy is 
obtained. Thus, the 10-fold stratified cross validation ensures that the models are validated on 
independent data. 
Both the Multilayer Perceptron and the 10-fold stratified cross validation were implemented using 
MATLAB version 7.8.0.     
Results 
Optimal Structure of Multilayer Perceptron 
The first part of the study was to identify the best structure for the Multilayer Perceptron model for 
the given data set. The optimal MLP structure was defined by conducting 10-fold stratified 
classification experiments on the pre-processed dataset described above. The outcome, “class” 
variable that is the categorised value of INR day7 was represented by a single node in the Perceptron 
output layer, coded as class “1” for “under load”, class “2” for “in therapeutic range”, and class “3” 
for “over load”. The number of hidden layers/nodes, learning rate, number of training iterations, as 
well as combination of activation functions for the hidden and output nodes were varied to define 
the optimal Perceptron structure to produce the best accuracy classification. 
 
 
Figure 2: Average classification accuracy obtained by different activation functions. 
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First, the best combination of activation functions for hidden and output layer nodes was defined for 
a Perceptron with a single hidden layer consisting of 5 hidden nodes, a fixed learning rate of 0.15 
was set and with a run of 100 iterations. The average accuracy obtained from different combinations 
of activation functions is shown in Figure 2, where “purelin” is the pure linear activation function, 
“logsig” is logarithmic sigmoid activation function and “tansig” is tangent sigmoid activation 
function. The default Matlab setting is the logarithmic sigmoid activation function for hidden 
neurons with the pure linear activation function for the output neurons.   
It was found that the tangent sigmoid function is the best activation function for both the hidden 
and output layers, as it gives an average accuracy rate of 0.649 for the data set. Further experiments 
to determine the best learning rate and corresponding iteration times identified 0.04 as the best 
learning rate and 3000 to be the optimal number of iterations. With this learning rate and number of 
iterations, the average accuracy was increased to 0.835. Finally, further experiments were carried 
out to investigate whether increasing the number of hidden layers/nodes would improve the 
accuracy rate; however it proved not to be the case. The final perceptron model contained a single 
hidden layer with 5 nodes, with the tangent sigmoid activation function use in all hidden and output 
nodes, the learning rate was 0.04, and was run for 3000 iterations.   
Data Quality. 
To appreciate the importance of data quality, classification using the pre-processed dataset and the 
original dataset with missing data was conducted. In the original data set, the instances with missing 
INR values on day 7 were labelled as an additional category 4, all other missing values were replaced 
with 0. Missing data represents a particular type of noise in a data set and different methodological 
techniques can be used to deal with it. For continuous numerical covariates it may be sensible to 
replace missing data with an average or average for the “class”. However, it is not possible to 
replace categorical missing data with an average; for example, sex, or genotype, even average age 
may not make sense as the noise will still be there. From this point of view simple replacement of a 
missing data with 0, is just as plausible as labelling it as “noise” in the pattern, and quantify the 
effect of the noise on classification than trying to smooth it out.  The classification outcomes using 
the pre-processed dataset and the original dataset with missing data are shown in Figure 3. The 
confusion matrices are used to show the correctly identified number of instances as “true” class on 
the main diagonal, with misclassified “false” class instances above and below the main diagonal. 
Note as 10-fold cross validation was used for all classification experiments, the average number of 
instances for each "true" and "false" classification is shown in the confusion matrices rather than 
counts of individuals, hence the reporting of decimal values.  For example, in Figure 3a (line 1), there 
is an average of 55.2 patients in category 1 correctly identified using the 10-fold cross validation, 
average of 13.8 patients of category 2 patients wrongly identified as being in category 1, and 
average of 1.2 category 3 patients wrongly identified as being in category 1. The average percentage 
of correctly identified patients (e.g. 78.6% for class 1) is given in column 4. Cell 2 in column 1 shows 
average number of patients in category 1 wrongly classified as category 2. Cell 3 in column 1 shows 
average number of patients in category 1 wrongly classified as category 3. The bottom cell 4 in 
column 1 shows average percentage (78.9%) of correctly identified/recalled patients in category 1.  
Also, in Figure 3b, as all instances of class 4 that is "missing INR day 7" had to be identified as either 
class 1, 2, or 3, there is empty "true" cell for the class 4. 
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                      a) Pre-processed dataset                                                              b) Original dataset 
 
Figure 3: Confusion matrix for classification using a) pre-processed and b) original dataset. 
According to the confusion matrices in Figure 3, the classification performance of the pre-processed 
dataset is much better than the original dataset which included the missing data. Especially for class 
1, the under-loads, the accuracy rate for the original dataset is only 17.4% whereas the pre-
processed dataset has an accuracy rate of 78.9%. Although the Perceptron algorithm has the ability 
for dealing with missing values, up to some critical amount, missing values have a negative influence 
on the accuracy rate. The results demonstrate that the percentage of missing values in the 
unprocessed original data set was high, resulting in poor classification performance, particularly on 
the classes which contain fewer observations.     
Optimal set of covariates. 
For the reasons discussed above, in the original data set, and even after pre-processing, there were 
many missing interim INR measurements on days 4, 5, and 6, with particularly scarce data on INR 
day 5 and 6. On the other hand, as our unpublished work (Lane and Biktasheva, 2008) showed  
patients given a too conservative loading regimen were unlikely to achieve an on  INR day 7 within 
the therapeutic range, it was important to investigate the classification effect of the total loading, 
consequently this measurement was included in the analysis as an additional covariate. Therefore, 
five possible combinations of covariates in the data set, shown in Table 1, with presence/absence of 
total loading and the interim INR measurements on days 4, 5, and 6 were tested for classification 
outcome. 
Data Set № INR day 4 INR day 5 and 6 Total Loading Comments 
1 + + - 
The original  
pre-processed 
data set 
2 + - -  
3 - - -  
4 + - +  
5 - - + 
Optimal,  
best classification 
Table 1: Data sets used to identify optimal combination of covariates. 
To determine what role the infrequently measured covariates, INR day 4, 5, and 6, might have on the 
classification results, first, INR day 5 and day 6 were deleted from the pre-processed data set (Data 
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Set 2 in the Table1), and the experiments were repeated on this reduced number of covariates. 
Then, the experiments were repeated with the pre-processed data set with all three covariates INR 
day 4, 5, and 6 deleted (Data Set 3 in the Table1). The classification results are shown in Figure 4. 
 
                a) Dataset without INR day 4, 5 and 6                              b) Dataset without INR day 5 and 6 
   
Figure 4: Confusion matrices for classification with the a) data set 3, and b) data set 2, as in Table 1. 
It can be seen by comparison of Figures 3a and 4b, that elimination of the interim measurements of 
INR day 5 and 6, improves classification of classes 1 and 2, the “under-load” and “in therapeutic 
range” categories, but  reduces classification accuracy for class 3 “over-load”. Further elimination of 
the covariate INR day 4, improves classification of classes 2 and 3, the “in therapeutic range” and 
“over-load” group, but again reduces classification accuracy for class 3 “over-load”. Consequently, at 
this stage, it is difficult to say whether or not the classification improvements were due to the 
elimination of missing data, or the covariates INR day 5, 6, 7 which have some effect on classification 
accuracy for the classes having fewer observations. However, comparing Figures 3a and 4a, 
classification without INR day 4-6 is much better for all categories than the one obtained on the pre-
processed data with the complete original set of covariates. 
Finally, to check if the total loading dose improves classification, it was included the model as an 
extra covariate.  The results are shown in Figure 5. 
 
    a) Dataset “total dosage + INR day 4”                                    b) Dataset “total dosage only” 
 
Figure 5: Confusion matrices for classification experiments with datasets 4 and 5, as in Table 1. 
From comparison of Figures 4a and 5b, it can be seen that adding the total loading dose to the data 
set 3 in Table 1, that is without INR day 4-6, further improves the classification rate for all three 
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classes, so the average classification rate data set 5 in Table 1 is very high 86.3%, with 82.6% 
accuracy on the smaller "under-load" category 1, and 88.3% on the large "in therapeutic range" 
category 2. 
From comparison of Figures 5a and 5b, it can be seen that again the addition of the covariant INR 
day4 has a significant negative effect on classification for all the three classes.   
Discussion 
Although one previous study, Solomon et al, 2004, has successfully applied neural network 
techniques to Warfarin maintenance dose prediction, and there have been a number of linear 
regression models proposed for estimating the maintenance dose, this is the first study that has 
investigated the individual’s response to the initial loading dose phase. One major problem with 
estimating the response to the loading dose is that an individual INR level is subject to high daily 
variability, and in many cases individuals do not reach a steady state. However, due to the high risk 
of adverse drug reactions associated with Warfarin, it is important that both loading and 
maintenance dosing regimens are as individualised as possible. A number of demographic variables, 
genotypes, along with co-medication and diet have been identified as possible causes of the high 
inter-individual variability in dose requirements and response to the drug.     
The Day 7 INR value was chosen as the output variable, because it was thought to provide the first 
indication of the individual’s steady state INR value. Earlier measurements taken on days 4 or 5 are 
still subject to high fluctuations and the perceptron model demonstrated that when these 
measurements were included as explanatory variables they had a negative impact on the accuracy of 
the model. However, the model did demonstrate that by combining the individuals loading dose, in 
this case three daily doses of Warfarin, along with known demographic and genotype information it 
was possible to classify the individual’s response at day 7 with a high degree of accuracy. This 
accuracy was improved further when the total three day loading dose was added to the model.    
The initial accuracy of the model to correctly classify an individual’s response to their prescribed 
loading dose was 78.9% for those who failed to achieve target INR, 85.0% for those who achieved 
the therapeutic range, and 85.0% for those who were above the therapeutic range. When total 
dosage was added to the model the accuracy in classification rates increased to 82.6%, 88.3% and 
85.4% respectively. 
Further development of the algorithm to predict the optimum loading dose for an individual to 
achieve the therapeutic range will be of a particular value to clinicians. This is to be the subject of a 
follow-up study.  
Conclusion 
The study demonstrates that the perceptron algorithm can be used to classify a patient’s response 
to a specific loading dose regimen given demographic and genetic information. Consequently, at day 
0 the clinician can test different loading dose strategies, (e.g. 10, 10, 5 or 8, 8, 7) with the known 
demographic and genetic information to predict the individual’s response, in-terms of being below, 
within or above the required therapeutic range at day 7. 
The stratified cross validation warrants the models testing on independent data and  generalization 
of the results to the complete data set. The algorithm has good accuracy for classifying the patient’s 
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response and could be implemented into clinical practice, as an aid to ensuring that patients receive 
the best possible dose to achieve therapeutic INR and reduce the risk of adverse drug reactions.   
The neural networks methods seem to take better account of this implicit nonlinear link between 
the patients characteristics, the Warfarin loading dosage and individual patients response. 
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